Martin Shkreli’s old company touts PhIII win, guns for accelerated approval
Three months after rebranding to shed the last of its ties to convicted “Pharma Bro” Martin Shkreli, Travere Therapeutics is putting its best foot forward with an upbeat Phase III analysis and plans to seek accelerated approval in a rare kidney disorder.
Travere — formerly known as Retrophin — says its lead candidate sparsentan met the pre-specified interim endpoint in a study of 371 patients who have focal segmental glomerulosclerosis, a disorder where kidneys’ filtration breaks down and proteins leak into the urine. For many patients, the disorder leads to end-stage kidney disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.